Acadian Asset Management LLC Gritstone Bio, Inc. Transaction History

Acadian Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.28 - $2.85 $48,477 - $107,938	37,873 New	37,873 $77,000
Q1 2022 May 12, 2022	SELL	$4.03 - $12.19 $1.8 Million - $5.46 Million	-447,611 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$8.76 - $13.71 $1.37 Million - $2.15 Million	-156,869 Reduced 25.95%	447,611 $5.76 Million
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $518,908 - $1.1 Million	80,953 Added 15.46%	604,480 $6.53 Million
Q2 2021 Aug 11, 2021	BUY	$8.13 - $10.2 $4.26 Million - $5.34 Million	523,527 New	523,527 $4.78 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.